Brian Richard Macdonald net worth and biography

Brian Macdonald Biography and Net Worth

Insider of Disc Medicine

Brian is the Chair of Disc Medicine’s Scientific Advisory Board after previously serving as Chief Innovation Officer and founding CEO of Disc Medicine. Prior to Disc he was the Founder and CEO of Merganser Biotech, where he worked on minihepcidin peptides. He has 25 years of drug development and executive management experience in a range of different therapeutic areas at companies that include Zelos Therapeutics, 3-Dimensional Pharmaceuticals and GlaxoSmithKline. He is a research physician with an academic and clinical background in musculoskeletal biology and rheumatology. He received his MB, ChB and PhD from the University of Sheffield and is a Member of the Royal College of Physicians.

What is Brian Richard Macdonald's net worth?: The estimated net worth of Brian Richard Macdonald is at least $674,831.16 as of June 30th, 2023. Macdonald owns 12,876 shares of Disc Medicine stock worth more than $674,831 as of March 14th. This net worth approximation does not reflect any other investments that Macdonald may own. Learn More about Brian Richard Macdonald's net worth.
How do I contact Brian Richard Macdonald?: The corporate mailing address for Macdonald and other Disc Medicine executives is 297 Boston Post Road #248, Wayland MA, 01778. Disc Medicine can also be reached via phone at 617-401-4400 and via email at ir@geminitherapeutics.com. Learn More on Brian Richard Macdonald's contact information.
Has Brian Richard Macdonald been buying or selling shares of Disc Medicine?: Brian Richard Macdonald has not been actively trading shares of Disc Medicine over the course of the past ninety days. Most recently, Brian Richard Macdonald sold 4,324 shares of the business's stock in a transaction on Friday, June 30th. The shares were sold at an average price of $45.05, for a transaction totalling $194,796.20. Following the completion of the sale, the insider now directly owns 12,876 shares of the company's stock, valued at $580,063.80. Learn More on Brian Richard Macdonald's trading history.
Who are Disc Medicine's active insiders?: Disc Medicine's insider roster includes Mona Ashiya (Director), Kevin Bitterman (Director), Joanne Bryce (CFO), Jean Franchi (CFO), Rahul Khara (Insider), Brian Macdonald (Insider), John Quisel (CEO), William Savage (Insider), Pamela Stephenson (Insider), William White (Director), and Jonathan Yu (COO). Learn More on Disc Medicine's active insiders.
Are insiders buying or selling shares of Disc Medicine?: During the last year, insiders at the sold shares 19 times. They sold a total of 395,005 shares worth more than $22,156,241.87. The most recent insider tranaction occured on March, 12th when Director Mona Ashiya sold 83,182 shares worth more than $4,529,259.90. Insiders at Disc Medicine own 4.2% of the company. Learn More about insider trades at Disc Medicine.
Information on this page was last updated on 3/12/2025.

Brian Richard Macdonald Insider Trading History at Disc Medicine

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
6/30/2023	Sell	4,324	$45.05	$194,796.20	12,876

Brian Richard Macdonald Buying and Selling Activity at Disc Medicine

Disc Medicine Company Overview

Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. The company's preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Disc Medicine, Inc. was founded in 2017 and is headquartered in Watertown, Massachusetts.

Today's Range

Now: $53.05

$52.36

$54.84

50 Day Range

MA: $56.62

$53.37

$63.82

2 Week Range

Now: $53.05

$25.60

$68.86

Volume

263,058 shs

Average Volume

359,837 shs

Market Capitalization

$1.83 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.73